This paper shows massive relief using DMSO Zinc-iodide solution from symptoms of COPD. Click on the website link below to see the tables showing the studies results.
researchgate.net
Abbreviations:
SpO2 : peripheral capillary oxygen saturation
DMSO : Dimethyl Sulfoxide
COPD : chronic obstructive pulmonary disease
ZIDS : Zinc iodide and dimethyl sulfoxide
Introduction
Chronic respiratory diseases such as chronic obstructive pulmonary
disease and asthma, and interstitial lung disease are the most common
non-communicable diseases worldwide [1]. Chronic respiratory diseases
have received proportionately less public attention and less research
funding than other diseases such as cardiovascular disease, cancer, stroke,
diabetes, and Alzheimer's disease [2, 3]. COPD continues to be a
significant medical problem and is the third leading cause of death in the
United States. Acute bronchitis and acute exacerbations of COPD are
among the most common illnesses encountered by family physicians and
account for more than 14 million physician visits annually. The mortality
rate of hospitalized COPD patients because of acute exacerbation is about
10% [4]. The circumstances mentioned above indicate that exploring a
more effective, safe, and less expensive approach targeting the prevention
and treatment of chronic respiratory diseases is crucial and imperative for
global health.
Asthma, COPD, and other chronic respiratory diseases are characterized
by chronic inflammation and tissue remodeling of the airways.
Remodeling is resistant to pharmaceutical therapies. Our published study
reported that zinc and methylsulfonylmethane (organic sulfur
compounds) potentially prevent airway wall remodeling in asthma by
inhibiting both the Erk1/2 and mTOR signaling pathways [5]. In our prior
publication, we have also proposed a possible application of Zinc Iodide
-Dimethyl Sulfoxide (ZIDS) composition to treat the respiratory
symptoms and complications in patients with COVID-19 [6].
In this retrospective observational study, we have followed up, analyzed,
and reported a series of anecdotal cases of patients with chronic
respiratory diseases who have been treated with ZIDS composition in
adjunction to the standard of care treatment.
Open Access
Research Article
New Medical Innovations and Research
Ba X Hoang *
AUCTORES
Globalize your Research
J. New Medical Innovations and Research Copy rights@ Ba X Hoang et.al.
Auctores Publishing LLC – Volume 3(1)-030 www.auctoresonline.org
ISSN: 2767-7370 Page 2 of 5
Research Material:
ZIDS composition (water solution of 30% DMSO pharmaceutical grade
and 0.2% of Zinc Iodide) has been developed in the Nimni-Cordoba
Tissue Engineering and Drug Discovery Laboratory of the Department of
Surgery, Keck School of Medicine of the University of Southern
California, in cooperation with Thai Minh Pharmaceutical Company.
ZIDS has been tested for acute and chronic toxicity, skin and mucosal
irritation, and thyroid toxicity by the Pharmacology Department of the
National Institute of Drug Quality Control of Vietnam. The testing results
showed an excellent safety profile and tolerability.
Research ethics:
Patients were asked to give their consent to participate in the trial.
Patients have the right to withdraw from the study at any time and for any
reason. The study is a retrospective and observational study that had no
approved protocol.
Observational clinical evidence
Observation 1:
Eight moderate to severe asthmatics (5 men and 3 women) aged 28–74
years old were treated with 10 ml of ZIDS mixing with 200 ml of water,
three times daily orally in 2 hours after meals for 60 days. These patients
have been diagnosed with asthma and have had anti-asthmatic drugs for
6–21 years. The patients presented with episodes of dyspnea, excessive
mucus expectoration, coughing, wheezing, or chest tightness more than
four times a week and woke up at night with asthma symptoms more than
four times a week. The patients took moderate and high doses of
medications defined as at least 1,800 mcg of ß2-agonists (short-acting or
equivalent of long-acting) per week and inhaled corticosteroids (400–
2000 µg/day) of beclomethasone dipropionate or equivalent. Their
morning peak expiration flow (PEF) was less than 84% predicted as the
baseline. Two patients were on oral corticosteroid in the form of
prednisolone: 10 mg and 20 mg per day. Results of the treatment with
ZIDS in adjunction with a standard of care are summarized and recorded
in a diary card of symptoms, PEF, medication use, and quality of
assessment life.
The patient’s records were analyzed retrospectively and compared with
the baseline data. All patients were followed for 60 days, evaluated every
week for the ?rst month and every two weeks for the second month of
therapy with oral administration ZIDS solution. The mean PEF of all
patients was 72 % as the baseline.
The progression and treatment results of the patients are presented in
Table 1.
Table 1: Clinical symptoms, treatment doses, and PEF changes at four time points
After one week from the start of the ZIDS oral treatment, the patients
recorded a reduction of daytime asthma symptoms by 70% and nighttime
symptoms by 75%. Short and long-acting ß2-agonists doses had been
reduced by 50%. The corticosteroids dose inhaled was decreased by 50%.
The usage of oral prednisolone was lowered to 75%. The mean PEF rate
improved by 15%, and no additional side effects were recorded. The
patients’ blood pressures and pulse rates were within normal ranges.
After two weeks from starting treatment, the daytime and nighttime
asthma symptoms were reduced by 85%. The ß2-agonist dose was
reduced by 75%, the corticosteroid inhaler dose was decreased by 65%,
and the usage of oral prednisolone was lowered to 50%, the mean PEF
rate improved by 20%, with no side effects observed.
At the end of 30 days, both daytime and nighttime asthma symptoms were
reduced by 90%. The ß2-agonists use was reduced by 95%, the
corticosteroid inhaler dose was reduced by 90%, and the usage of oral
prednisolone was terminated. The mean PEF value increased by 22%,
and no additional side effects were recorded.
After 60 days of the treatment with ZIDS, the daytime symptoms of
asthma reduced by 95%, and nighttime symptoms were reduced by 95%.
The ß2-agonist use was terminated, and the corticosteroid inhaler was
decreased by 95%. The mean PEF increased by 25 %. 6 out of 8 treated
patients have reached an asymptomatic and medication-free state.
From the beginning to the end of treatment, there were no additional side
effects observed in ZIDS treated patients compared to the baseline level.
The mean PEF rate improved after one week, and this trend continued for
two weeks, 30 days, and 60 days following the treatment. The patients’
blood pressures and pulse rates improved in 5 of 8 patients after 30 days
and 6 of 8 patients after 60 days of treatment with adjunctive ZIDS
solution. The general blood count test, general blood chemistry profiles,
and thyroid hormone profiles were normal in 30 days and 60 days points
of ZIDS treatment. All patients reported improved general health, quality
of life, and sleep patterns.
Observation 2:
Seven patients (6 males and 1 female), age range from 45 to 83, with a
history of chronic cough and COPD, all presented with episodes of COPD
exacerbations. All patients presented with comorbidity, including asthma
(2 cases), diabetes (3 cases), hypertension (5 cases), ischemic heart
disease (4 cases), pneumonia (1 case), arthritis (3 cases), liver diseases (2
cases), chronic gastritis (5 cases) and stomach ulcers (2 cases).
All patients received treatment with 10 ml ZIDS solution mixed with 200
ml of water three times daily 2 hours after meals at home. The patients
were allowed to take all the medications for COPD and comorbidities in
the same regimen and doses before exacerbations; no additional
medications were added besides the ZIDS solution.
Monitoring clinical changes and paraclinical parameters was performed
at three-time points: enrolment day (day 1, baseline), 15 days of the
treatment (day 15), and 30 days (day 30) of the treatment with ZIDS in
addition to a baseline standard of care. Clinical parameters, including
severe cough, dyspnea, sputum secretion, fever, chest tightness, capacity
for exercise and activities, sleep quality, and energy levels, were scored
J. New Medical Innovations and Research Copy rights@ Ba X Hoang et.al.
Auctores Publishing LLC – Volume 3(1)-030 www.auctoresonline.org
ISSN: 2767-7370 Page 3 of 5
based on the modified Medical Research Council Dyspnea Scale
(mMRC) questionnaire [7, 8].
Other paraclinical parameters such as general blood count tests, general
blood biochemistry profiles, and Pulmonary Function Tests (Spirometry)
were recorded. (Table 2)
As shown in Table 2, the patients reported improvement in all symptoms
related to COPD exacerbation after 15 and 30 days of therapy with ZIDS
in addition to baseline treatment for COPD and comorbidity compared to
the baseline.
Table 2: Clinical Changes at Three Time Points (Day- 1, Day-15, and Day- 30)
The mMRC dyspnea scale was used in our study to assess the effectiveness of ZIDS treatment on an individual basis. From a clinical viewpoint, the
mMRC scale correlates well to such objective measures as pulmonary function tests [9, 10]. (Table 3)
Table 3: Modified Medical Research Council scale (mMRC)
As presented in Table 4, the recorded mMRC scale showed the patients' improvement in functional activities, quality of life, and general health after
15 days and 30 days of treatment with adjunctive ZIDS to baseline treatment for COPD and comorbidity. (Table 4)
Table 4: Clinical changes at three time points by mMRC scale
The improvement of patients’ pulmonary function compared to baseline with adjunctive SIDS treatment is reported in Table 5.
(Table 5)
Table 5: Functional pulmonary test results
Retrospective analysis of the patients showed that oral ZIDS was effective
as adjunctive therapy for COPD exacerbation leading to a fast reduction
of the patients’ symptoms, improvement in pulmonary functional
parameters, quality of life, and physical function. All these were
documented in Tables 2, 4, and 5.
J. New Medical Innovations and Research Copy rights@ Ba X Hoang et.al.
Auctores Publishing LLC – Volume 3(1)-030 www.auctoresonline.org
ISSN: 2767-7370 Page 4 of 5
After 30 days of treatment, all seven patients showed an overall
improvement; no additional adverse effects were reported in the treated
patients compared to the baseline.
Discussion
Treatments for chronic respiratory diseases are challenging and costly.
Currently, none of the approved drugs or treatments can cure asthma,
COPD and respiratory complications of autoimmune diseases.
Treatments can reduce symptoms and prevent exacerbations; however,
the need for life-long administration and severe side effects of the most
common anti-inflammatory and symptomatic therapeutic agents are the
challenging problems in respiratory medicine.[4, 11-13]
The clinical evidence of our current retrospective study indicated a
possible implementation of old and approved pharmaceutical (nutritional)
agents such as Zinc, Iodine, and organic sulfur compounds for
management of asthma, COPD and other respiratory diseases.
The comprised ingredients' synergic and complex biological properties
might produce viable anti-inflammatory, immunoregulatory, antioxidant,
antiviral, antibacterial, antifungal, and antifibrotic therapeutic activities
that resulted in favorable clinical benefits with a good safety profile of
ZIDS composition [6, 14, 15]. ZIDS composes of well-characterized
OTC pharmaceutical ingredients with a favorable safety profile.
Therefore, it is a significant advantage for developing and applying ZIDS
as a repurposed therapeutic product for acute and chronic respiratory
diseases since new medications may take many years.
A future well-designed clinical trial is warranted to explore more potential
therapeutic activities of ZIDS and promote a possible wider application
of this potential therapeutic composition for the management of
respiratory diseases.
Conclusion
The current observational retrospective study results demonstrate that
ZIDS might effectively treat respiratory diseases. More extensive control
trials will be needed to confirm the study findings.
Declaration of Competing Interest
None of the authors declares a conflict of interest regarding the data
presented in this publication.
Funding
This study was investigators initiated and non-funded.
References
1. James, S.L., et al., Global, regional, and national incidence,
prevalence, and years lived with disability for 354 diseases
and injuries for 195 countries and territories, 1990–2017: a
systematic analysis for the Global Burden of Disease Study
2017. The Lancet, 2018. 392(10159): p. 1789-1858.
2. Boehm, A., et al., Assessing global COPD awareness with
Google Trends. European Respiratory Journal, 2019. 53(6).
3. Gross, C.P., G.F. Anderson, and N.R. Powe, The relation
between funding by the National Institutes of Health and the
burden of disease. New England Journal of Medicine, 1999.
340(24): p. 1881-1887.
4. Hoang, B.X., et al., Nutritional Supplement “Bao Khi Khang”
as an Adjuvant Therapy in Acute Exacerbations of Chronic
Obstructive Pulmonary Disease. Journal of medicinal food,
2018. 21(10): p. 1053-1059.
5. Fang, L., et al., Zinc salicylate reduces airway smooth muscle
cells remodelling by blocking mTOR and activating p21
(Waf1/Cip1). The Journal of Nutritional Biochemistry, 2021.
89: p. 108563.
6. Hoang, B.X., H.Q. Hoang, and B. Han, Zinc Iodide in
combination with Dimethyl Sulfoxide for treatment of SARS-
CoV-2 and other viral infections. Medical hypotheses, 2020.
143: p. 109866.
7. Munari, A.B., et al., Modified Medical Research Council
dyspnea scale in GOLD classification better reflects physical
activities of daily living. Respiratory care, 2018. 63(1): p. 77-
85.
8. Rajala, K., et al., mMRC dyspnoea scale indicates impaired
quality of life and increased pain in patients with idiopathic
pulmonary fibrosis. ERJ open research, 2017. 3(4).
9. Manali, E.D., et al., MRC chronic Dyspnea Scale:
Relationships with cardiopulmonary exercise testing and 6-
minute walk test in idiopathic pulmonary fibrosis patients: a
prospective study. BMC pulmonary medicine, 2010. 10(1): p.
1-10.
10. Perez, T., et al., Modified Medical Research Council scale vs
Baseline Dyspnea Index to evaluate dyspnea in chronic
obstructive pulmonary disease. International journal of
chronic obstructive pulmonary disease, 2015. 10: p. 1663.
11. Page, C. and M. Cazzola, Bifunctional drugs for the treatment
of asthma and chronic obstructive pulmonary disease.
European Respiratory Journal, 2014. 44(2): p. 475-482.
12. Korsgaard, J. and M. Ledet, Potential side effects in patients
treated with inhaled corticosteroids and long-acting ß2-
agonists. Respiratory medicine, 2009. 103(4): p. 566-573.
13. Hoang, B.X., et al., New approach in asthma treatment using
excitatory modulator. Phytotherapy Research: An
International Journal Devoted to Pharmacological and
Toxicological Evaluation of Natural Product Derivatives,
2007. 21(6): p. 554-557.
14. Hoang, C., et al., Application of Dimethyl Sulfoxide as a
Therapeutic Agent and Drug Vehicle for Eye Diseases.
Journal of Ocular Pharmacology and Therapeutics, 2021.
37(8): p. 441-451.
15. Hoang, B.X. and B. Han, Micronutrient zinc roles in
adjunctive therapy for COVID-19 by enhancing patients
immunoregulation and tolerance to the pathogen. Reviews in
Medical Microbiology, 2021. 32(3): p. 149-157.
J. New Medical Innovations and Research Copy rights@ Ba X Hoang et.al.
Auctores Publishing LLC – Volume 3(1)-030 www.auctoresonline.org
ISSN: 2767-7370 Page 5 of 5
|
